CYP2D6 Genotyping by AmpliChipTM CYP450 for Tamoxifen-Treated Breast Cancer Patients
NCT00815555 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 500
Last updated 2008-12-30
Summary
The aim of the study is to examine whether tamoxifen-treated Israeli breast cancer patients who are CYP2D6 poor metabolizers (CYP2D6\*4/\*4 genotype) are at higher cancer relapse risk during 2.5-5-year follow-up period from initial diagnosis and primary treatment.
Conditions
Interventions
- OTHER
-
There is no intervention - this is an observational study
Sponsors & Collaborators
-
Assaf-Harofeh Medical Center
lead OTHER_GOV
Eligibility
- Min Age
- 18 Years
- Sex
- FEMALE
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2008-12-31
- Primary Completion
- 2011-12-31
Countries
- Israel
Study Locations
More Related Trials
-
Evaluation of the Association Between CYP2D6 Genetic Polymorphisms and the Treatment Effect of Tamoxifen
NCT00532454 ·Status: TERMINATED ·Phase: PHASE2
-
Studying Blood Samples From Women With Breast Cancer or Ductal Carcinoma In Situ Who Are Receiving Tamoxifen
NCT00764322 ·Status: COMPLETED ·Phase: PHASE2
-
Genetic Study of CYP2D6 Enzyme and Therapeutic Drug Monitoring of Tamoxifen
NCT03582865 ·Status: UNKNOWN
-
The Clinical and Economic Impact of Pharmacogenomic Testing for Tamoxifen Metabolism in Postmenopausal Women Receiving Tamoxifen for Prevention of Recurrent Breast Cancer
NCT00830973 ·Status: COMPLETED
-
Tamoxifen Citrate in Treating Patients With Metastatic or Recurrent Breast Cancer
NCT01124695 ·Status: COMPLETED ·Phase: PHASE2
-
Tamoxifen Pharmacogenetics in Asian Breast Cancer Women
NCT01181518 ·Status: UNKNOWN
-
CYP2D6 Genotype on the Clinical Effect of Tamoxifen
NCT00973037 ·Status: UNKNOWN
-
Oral Tamoxifen vs. TamGel vs. Control in Women With Atypical Hyperplasia, Lobular Carcinoma In Situ, or Increased Breast Cancer Risk
NCT04570956 ·Status: TERMINATED ·Phase: PHASE2
-
Tamoxifen Pharmacokinetics and CYP2D6 Polymorphisms in Asian Women With Hormone Receptor Positive Breast Cancer
NCT00717015 ·Status: COMPLETED
-
Aromatase (CYP19) Polymorphism Between AI-responsive and AI-resistant Breast Cancer in Korea
NCT01137136 ·Status: SUSPENDED
-
Genotyping and Phenotyping of CYP2D6 Breast Cancer Patients on Tamoxifen
NCT03504631 ·Status: UNKNOWN
-
CYP2D6 Genotypes and Breast Cancer Clinical Outcomes in the Indonesian Population
NCT05501158 ·Status: UNKNOWN ·Phase: NA
-
Study of CYP2C19 and ALDH3A1 Polymorphisms in Breast Cancer Patients
NCT04581967 ·Status: UNKNOWN
-
Tamoxifen Resistance in Women With Stage I, Stage II, Stage IIIA, or Stage IIIB Breast Cancer
NCT00899197 ·Status: TERMINATED
-
Efficacy of Tamoxifen Versus Toremifene in CYP2D6 IM/PM of Premenopausal Patients With ER-positive Early Breast Cancer
NCT03351062 ·Status: RECRUITING ·Phase: PHASE3
-
PharmacoKINEtics of TAMoxifen and Its Metabolites in Breast Cancer Patients: the Influence of a Dose Increase in Phenotypic Poor Metabolizers of CYP2D6 (KINETAM)
NCT01192308 ·Status: COMPLETED ·Phase: PHASE1
-
Analyzing a New Mechanism in Response to Tamoxifen Therapy in Breast Cancer Patients
NCT01027416 ·Status: COMPLETED ·Phase: NA
-
Dose-determining and Dose-confirmatory Study to Investigate the Optimal Dose of Tamoxifen in Breast Cancer Patients According to Genotype Status of TCF20 rs932376
NCT04961632 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE1
-
A Study To Determine If Coadministration Of Tamoxifen Alters The Extent Or Rate Of Palbociclib (PD-0332991) Absorption Or Elimination In Healthy Male Volunteers
NCT01821066 ·Status: COMPLETED ·Phase: PHASE1
-
A Study to Evaluate Exemestane Tablets Combined With Ovarian Function Suppression/Ablation in Treatment of Premenopausal Breast Cancer Patients With CYP2D6*10 Mutations （STEP）
NCT03137368 ·Status: UNKNOWN ·Phase: PHASE3
-
Tamoxifen in Treating Women With High-Risk Breast Cancer
NCT00002542 ·Status: COMPLETED ·Phase: PHASE3
-
Pharmacogenetics as a Predictor of Toxicity in Pre-Menopausal Women Receiving Doxorubicin and Cyclophosphamide in Early Breast Cancer
NCT00352872 ·Status: TERMINATED
-
Trial of Low Dose Tamoxifen in Women With Breast Intraepithelial Neoplasia - Long Term Follow-up
NCT01357772 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE3
-
A Pilot Trial of Tamoxifen and 4-HPR (4-N-Hydroxyphenyl Retinamide) in Persons at High Risk for Developing Breast Cancer
NCT00001378 ·Status: COMPLETED ·Phase: PHASE1
-
A Phase I Trial of Tamoxifen and 9-Cis-Retinoic Acid in Breast Cancer Patients
NCT00001504 ·Status: COMPLETED ·Phase: PHASE1